<DOC>
	<DOCNO>NCT02240940</DOCNO>
	<brief_summary>The design study multi-center , prospective , single-arm clinical trial evaluate safety efficacy Parachute percutaneous leave ventricle partition system . The purpose trial use Parachute percutaneous leave ventricular partitioning system isolate malfunction portion leave ventricle patient symptoms heart failure due ischemic heart disease provide data require gain Chinese regulatory approval .</brief_summary>
	<brief_title>PARACHUTE China Approval Trial</brief_title>
	<detailed_description>CardioKinetix develop catheter-based treatment method use treat patient heart failure due ischemic heart disease ( left ventricle enlargement anterior wall myocardial infarction ) . This implant device , call `` Parachute , '' partition membrane place inside apex enlarge ventricle motion abnormality . The Parachute implant device isolate dysfunctional apex region ventricle , reduce ventricular volume , improve leave ventricular diastolic compliance . Patients approve enrollment screen cardiac CT MRI implant Parachute implant device ( study device ) . Patients receive appropriate medical therapy ( AAMT ) approve physician . The patient cohort include patient heart failure wall motion abnormality due previous myocardial infarction , leave ventricular ejection fraction ≤40 % ≥15 % , NYHA class II - IV（non-hospitalized ) . A maximum 30 patient enrol seven center . Patients pass screen transthoracic echocardiography ( TTE ) cardiac CT MRI enrol trial . After confirm patient meet enrollment qualification cardiac CT MRI evaluation , patient enrol trial implant Parachute device treat warfarin/aspirin anticoagulation therapy . In follow-up period 3 month , 6 month , 1 year surgery , clinical evaluation , TTE testing , functional assessment , 6-minute walk test , evaluation adverse event do .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age ≥ 18 year ≤ 79 year BMI &lt; 40 ` Left ventricle ejection fraction ≤40 % ≥15 % Previous transthoracic echocardiography show LV MI structural heart dysfunction represent LV wall motion abnormality ( WMA ) Appearance ischemic heart failure symptom ( NYHA class II `` nonhospitalized '' class IV ) follow anterior wall infarction within previous 60 day Left ventricle must appropriate anatomical structure ( size shape ) ; cardiac CT leave ventricular angiography use confirm implant appropriate Parachute device possible Have receive appropriate treatment accord ACC/AHA guideline Subject his/her legal representative inform nature study consent participate provision trial , sign ECapproved inform consent form , agree undergo postsurgery treatment plan followup requirement , able complete followup require followup examination . Significant ventricle wall motion abnormality addition anteroapical region Valvular stenosis regurgitation ( tricuspid , aortic , mitral valve ) &gt; 2+ Recent ( within 6 month ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) Requires longterm dialysis endstage renal disease onset sepsis active endocarditis Life expectancy time enrollment hospitalization &lt; 1 year Known allergy contraindication aspirin , heparin , warfarin , nitinol ( titanium nickel alloy ) , sensitivity contrast agent , sufficiently treat medication surgery Cardiogenic shock within 72 hour screen Pregnant planning become pregnant study period Participated clinical trial another drug medical device within 30 day screen The researcher determine patient compliance poor person unable complete study accordance requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Volume Reduction</keyword>
	<keyword>Pressure Reduction</keyword>
	<keyword>Ischemic Heart Failure</keyword>
	<keyword>LAD Infarct</keyword>
</DOC>